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A B S T R A C T   
We examined the pathogenicity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in cynomolgus 
macaques for 28 days to establish an animal model of COVID-19 for the development of vaccines and antiviral 
drugs. Cynomolgus macaques infected with SARS-CoV-2 showed body temperature rises and X-ray radiographic 
pneumonia without life-threatening clinical signs of disease. A neutralizing antibody against SARS-CoV-2 and T- 
lymphocytes producing interferon (IFN)-γ specifically for SARS-CoV-2 N-protein were detected on day 14 in one 
of three macaques with viral pneumonia. In the other two macaques, in which a neutralizing antibody was not 
detected, T-lymphocytes producing IFN-γ specifically for SARS-CoV-2 N protein increased on day 7 to day 14, 
suggesting that not only a neutralizing antibody but also cellular immunity has a role in the elimination of SARS- 
CoV-2. Thus, because of similar symptoms to approximately 80% of patients, cynomolgus macaques are 
appropriate to extrapolate the efficacy of vaccines and antiviral drugs for humans.   
1. Introduction 
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 
infection (COVID-19) has been spreading around the world since late 
2019 (Zhu et al., 2020), and WHO declared a pandemic on March 11, 
2020. Accumulating reports indicate varying degrees of illness including 
asymptomatic patients, patients with mild respiratory symptoms, and 
patients with acute respiratory distress syndrome (ARDS) requiring 
admission to an intensive care unit (ICU) (Huang et al., 2020; Guan 
et al., 2020; Z Xu et al., 2020). In addition to the development of vac-
cines and antiviral drugs specific for SARS-CoV-2, determination of the 
pathogenicity in patients with severe clinical signs of disease and 
development of therapeutics for severe cases are urgent issues. 
For the development of prophylactics and therapeutics for SARS- 
CoV-2 infection, not only in vitro studies but also in vivo studies are 
required for evaluation of their efficacy, especially estimation of in vivo 
efficacy, for which assessments with challenge infection are difficult in 
clinical trials. Therefore, animal models that show pathogenicity similar 
to that in humans are necessary for research and development of vac-
cines and antiviral drugs (Cleary et al., 2020). The results of several 
studies on experimental infection of SARS-CoV-2 in animals have been 
reported. In a mouse model, SARS-CoV-2 propagated in the lungs of 
human angiotensin-converting enzyme 2 (ACE2) transgenic mice but 
not in the lungs of wild-type mice, and the virus caused interstitial 
pneumonia in the ACE2 transgenic mice (Bao et al., 2020). However, 
co-expression of human ACE2 and endogenous mouse ACE2 may change 
the disease progression to recapitulate COVID-19. Wild-type Syrian 
hamsters are sensitive to SARS-CoV-2, which propagated in the lungs to 
cause viral pneumonia, indicating a useful small animal model (Chan 
et al., 2020; Imai et al., 2020). However, since the viral pneumonia was 
resolved within 2 weeks in Syrian hamsters and antibodies that react to 
hamster molecules in order to examine immune responses are not 
available, another model is required to examine the pathogenicity of 
severe COVID-19. SARS-CoV-2 also propagated and caused lung 
inflammation and pneumonia in rhesus and cynomolgus macaques (Yu 
et al., 2020; Williamson et al., 2020; Rockx et al., 2020; Munster et al., 
2020; Deng et al., 2020). The pathogenicity in macaques was examined 
until 21 days after virus infection in all of the studies except for one 
study (Deng et al., 2020), in which the reason for the prolonged detec-
tion of viral genes in patients and virus antigen specific-T-lymphocyte 
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responses were not revealed. Therefore, in the present study, we 
observed cynomolgus macaques infected with SARS-CoV-2 for 4 weeks 
and examined T-lymphocyte responses specific for SARS-CoV-2 antigen 
peptides. 
The macaque model, of which immune responses and metabolism 
resemble those of humans, is useful to extrapolate the efficacy of vac-
cines and antiviral drugs in humans against SARS-CoV-2. In our previous 
studies on influenza virus infection, various influenza viruses including 
pandemic and avian influenza viruses propagated in cynomolgus ma-
caques that showed clinical signs of disease similar to human symptoms 
(Itoh et al., 2009; Muramoto et al., 2014). In addition, we detected 
influenza viruses that were less sensitive to neuraminidase inhibitors in 
treated macaques, indicating a useful model for predicting the emer-
gence of a drug-resistant virus (Itoh et al., 2015; Suzuki et al., 2020). 
Therefore, we have used the cynomolgus macaque model to evaluate the 
efficacy of vaccines and antiviral drugs in influenza virus infection 
(Arikata et al., 2012, 2019; Nakayama et al., 2013; Kitano et al., 2014; 
Nguyen et al., 2020). In the present study, we expanded our experi-
mental system to establish a SARS-CoV-2 infection model in cynomolgus 
macaques for preclinical studies. 
We revealed the pathogenicity of SARS-CoV-2 in the cynomolgus 
macaques. SARS-CoV-2 propagated in respiratory tissues and caused 
body temperature rises in all of the macaques. However, viral pneu-
monia in X-ray radiographs was confirmed in one macaque, in which a 
neutralizing antibody against SARS-CoV-2 in plasma was detected. We 
also found a thrombus in the lung of a macaque infected with SARS-CoV- 
2 as reported in human cases (Wichmann et al., 2020). These results are 
similar to observations in human patients with COVID-19 (Zhu et al., 
2020). Compared to influenza virus infection, the rate of detection of a 
neutralizing antibody was low in macaques infected with SARS-CoV-2 
(Arikata et al., 2012;Wang et al., 2020a). In addition, we examined 
T-lymphocyte responses specific for SARS-CoV-2 antigen, which were 
not analyzed in the other macaque studies. Interferon (IFN)-γ responses 
with delayed interleukin (IL)-2 responses in antigen-specific T-lym-
phocytes might be related to virus elimination without a neutralizing 
antibody. Thus, cynomolgus macaques are an appropriate animal model 
of SARS-CoV-2 infection for the development of vaccines and antiviral 
drugs. 
2. Results 
2.1. SARS-CoV-2 propagation predominantly in the nasal and oral 
cavities of cynomolgus macaques 
We inoculated the SARS-CoV-2 JPN/TY/WK-521/2020 (WK-521) 
strain (Matsuyama et al., 2020) into the conjunctiva, nasal cavity, oral 
cavity, and trachea of three cynomolgus macaques to examine the 
pathogenicity of the strain. We collected swab samples to examine virus 
propagation in the macaques. The virus was detected in swab samples of 
the conjunctiva, nasal cavity, oral cavity, and trachea of all of the ma-
caques on day 1 (the day after virus inoculation) (Table 1). The virus was 
detected in nasal and oral swab samples of two macaques, CE0202M and 
CE0324F, until day 7. No infectious virus was detected in swab samples 
after day 10 or in homogenized tissue samples collected on day 28 at 
autopsy (listed in Table S1). On the other hand, a large number of viral 
RNA in the swab samples was detected on day 1 and gradually decreased 
until day 28 (Fig. S1). The SARS-CoV-2 N gene was detected in respi-
ratory and rectal samples of CE0202M until day 28. In CE0324F, a low 
copy number of the viral gene in the nasal swab was detected on day 28. 
In the nasal swab sample of CE1242F, approximately 104 gene 
copies/mL were detected on day 28. The results of viral gene detection 
were consistent with prolonged detection of viral genes in human 
specimens (Shi et al., 2020). 
2.2. Clinical signs of disease in macaques infected with SARS-CoV-2 
Cynomolgus macaques showed clinical signs of disease after infec-
tion with SARS-CoV-2 WK-521. All of the macaques showed significant 
rises in body temperature after virus inoculation (day 0 to day 3) 
(Fig. 1). Body temperatures of two macaques (CE0324F and CEE1242F) 
on day 1 were higher than 39.5 ◦C (Fig. 1B and C) and average tem-
peratures at nighttime from day 0 to day 3 were significantly higher than 
that on day − 1 (Fig. 1E and F). On the other hand, CE0202M showed a 
significant rise in body temperature only at night on day 0, day 1 and 
day 3 (Fig. 1A, D). Body weight of CE0324F decreased by 10% until day 
28 due to loss of appetite (Fig. S2A). No macaques showed clinical scores 
that reached a humane endpoint (Table S1). Therefore, infection with 
WK-521 induced mild clinical signs of disease that were varied in the 
macaques. 
Table 1 
Virus titers in swab samples from cynomolgus macaques infected with SARS-CoV-2.  
Virus titers in swab samples (log10TCID50/mL) 
Samplesa Animals Days after virus inoculation 
1 3 7 10 14 17 21 24 
Conjunctiva CE0202M 1.50 <b < < < < < <
CE0324F 1.50 < < < < < < <
CE1242F 2.67 < < < < < < <
Nasal cavity CE0202M 4.50 2.77 3.33 < < < < <
CE0324F 3.50 1.33 < 1.33d < < < < <
CE1242F 4.23 < 0.67c < < < < < <
Oral cavity CE0202M 4.83 1.50 1.67 < < < < <
CE0324F 2.50 < < 1.00e < < < < <
CE1242F 3.50 < < < < < < <
Trachea CE0202M 3.33 < < < < < < <
CE0324F 2.00 < 0.67 < < < < < <
CE1242F 3.50 < < < < < < <
Bronchus CE0202M 2.00 < < < < < < <
CE0324F < < 0.67 < < < < < <
CE1242F < < < < < < < <
a No virus was detected in rectal swab samples from day 1 to day 24. 
b <: Virus titers were under the detection limit (0.67 log10TCID50/mL). 
c < 0.67: One CPE-positive well was detected in quadruplicate culture of undiluted samples. 
d < 1.33: Three CPE-positive wells were detected in quadruplicate culture of undiluted samples. 
e < 1.00: Two CPE-positive wells were detected in quadruplicate culture of undiluted samples. 
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2.3. Viral pneumonia in macaques infected with SARS-CoV-2 
Viral pneumonia and/or bronchopneumonia were observed in cyn-
omolgus macaques infected with SARS-CoV-2. Chest X-ray radiographs 
revealed a ground glass appearance in the lungs, especially in the pe-
ripheral pulmonary areas, of CE0324F from day 3 to day 7 but not after 
day 10 (Fig. 2A–C). Saturation of percutaneous oxygen (SpO2) values in 
infected macaques at each sampling were higher than 90% during the 
study (Fig. S2B). At autopsy on day 28, demarcated bright redness was 
observed on the surface of the right lower lung of CE0202M (Fig. 2D), 
suggesting congestion or bleeding near the surface of the lung. Dark red 
and brown lesions were observed on the surfaces of right and left lower 
lungs of CE0324F (Fig. 2E). Small red areas were observed in the left 
lower lung of CE1242F (Fig. 2F). 
Histological pneumonia was observed in all of the macaques infected 
with WK-521. Thickened alveolar walls with infiltration of macrophages 
were observed in the lung with macroscopic lesions in CE0324F, indi-
cating a regenerative tissue (surrounded by arrowheads, Fig. 3A). A 
larger number of bronchus-associated lymphoid tissues (BALT) were 
formed in the lung tissues of CE0324F (arrowhead, Fig. 3B) and 
CE1242F (Fig. S3B) than in those of CE0202M (Fig. S3A, C). In 
CE0202M, congestion (small arrowheads) and a thrombus (arrow) in the 
lung blood vessels were detected (Fig. 3D and E), and inflammatory 
exudate in the bronchus (arrow) and alveoli (small arrowhead) (bron-
chopneumonia) was observed in CE1242F (Fig. 3F). Lymphoid infiltra-
tion was detected in tissues other than respiratory organs. Focal 
lymphoid accumulation was seen in the submandibular gland of 
CE0324F (arrowhead, Fig. 3C). Thus, although no infectious virus was 
detected on day 28, lymphoid responses continued until day 28 after 
virus inoculation. 
2.4. Biochemical analysis of blood in macaques infected with SARS-CoV- 
2 
Organ functions after infection with SARS-CoV-2 were biochemically 
analyzed. Levels of alanine aminotransferase (ALT) and alkaline phos-
phatase (ALP) in plasma of CE0324F and CE1242F were increased on 
day 1 and day 3 after virus infection, but their levels including total 
bilirubin were within normal ranges, indicating minimal damage of 
hepatocytes as reported in patients without liver disease (Singh et al., 
2020) (Fig. 4A–C). No increase in the level of blood urea nitrogen (BUN) 
or creatinine was detected, indicating normal kidney function after virus 
infection (Fig. 4D and E). In CE0324F, the level of plasma amylase was 
temporally increased on day 1, suggesting transient damage to pancreas 
exocrine cells and/or salivary glands (Fig. 4F). 
2.5. Blood cell population in macaques infected with SARS-CoV-2 
The blood cell population in macaques infected with SARS-CoV-2 
was examined. The numbers of total white blood cells and gran-
ulocytes in CE0202M and CE1242F were increased temporally on day 1, 
but the number of total white blood cells in CE0324F was decreased on 
days 1 and 3 and it was increased after day 14 (Fig. 5A and B). The 
numbers of lymphocytes in the blood of CE0324F and CE1242F were 
decreased on day 1 and returned to the levels before infection on day 7 
to day 10 (Fig. 5C), whereas the numbers of monocytes in CE0324F and 
Fig. 1. Body temperature change in cynomolgus macaques after SARS-CoV-2 
infection. Cynomolgus macaques (n = 3) were inoculated with WK-521 on 
day 0. (A–C) Body temperatures of the macaques were recorded using telemetry 
transmitters and a computer. (D–F) Average body temperatures from 8 p.m. to 8 
a.m. the next day were calculated on the basis of data for individual macaques 
since temperatures during the daytime were affected by anesthesia (A–C). For 
example, the temperatures on day 0 mean average temperatures between 8 p.m. 
on day 0 and 8 a.m. on day 1 after virus inoculation. Average body tempera-
tures on each day were compared with those of day − 1 (from 8 p.m. on day − 1 
to 8 a.m. on day 0 before virus inoculation). Asterisks indicate significant dif-
ferences from average temperature on day − 1 (p < 0.05, Student’s t-test). 
Fig. 2. Viral pneumonia in cynomolgus macaques infected with SARS-CoV-2. 
(A–C) X-ray radiographs of CE0324F taken on day 0 before infection (A) and 
day 3 (B) and day 7 (C) after virus inoculation. Red circles indicate ground glass 
appearance (pneumonia). (D–F) Lung macroscopic appearance. All of the ma-
caques infected with the virus were autopsied 28 days after virus inoculation. 
White circles indicate lesions with a bright red or dark red/brown color. 
Fig. 3. Inflammation in lungs and salivary glands of cynomolgus macaques 
infected with SARS-CoV-2. Lungs and salivary glands were collected on day 28 
from macaques infected with SARS-CoV-2. HE-stained sections of lung tissues 
(A, B, D-F) and salivary glands (C). (A–C) CE0324F, (D, E) CE0202M, (F) 
CE1242F. (A) The area surrounded by arrowheads indicates thickened alveolar 
walls with infiltration of macrophages. (B, C) Arrowheads indicate bronchus- 
associated lymphoid tissues (BALT) and lymphoid infiltration. (D) Short ar-
rowheads indicate congestion. (E) Arrow: thrombus in a middle sized-blood 
vessel. (F) Inflammatory exudate in the bronchus (arrow) and alveoli 
(small arrowhead). 
H. Ishigaki et al.                                                                                                                                                                                                                                
Virology 554 (2021) 97–105
100
CE1242F were increased on day 7 and day 3, respectively (Fig. 5D). The 
numbers of platelets in CE0324F and CE1242F were decreased on day 3 
(Fig. 5E). Thus, two of the three macaques (CE0324F and CE1242F) 
showed apparent changes in the population of blood cells after SARS- 
CoV-2 infection. 
2.6. Immune responses in macaques infected with SARS-CoV-2 
Immune responses against SARS-CoV-2 in the cynomolgus macaques 
were examined. CE0324F showed marked changes in plasma cytokine 
levels after infection (Fig. 6). The levels of the inflammatory cytokine 
interleukin-6 (IL-6) together with levels of monocyte chemotactic 
protein-1 (MCP-1) and IL-10 on day 1 were higher than those before 
infection. Levels of the Th2 cytokines IL-4 and IL-13, Th17 cytokine IL- 
17, and chemokine MIP-1α were increased 10 days after virus infection 
and the level of IL-8 was increased 21 days after virus infection, 
although the changes in IL-17 and MIP-1α were small. Levels of the Th1 
cytokines interferon-γ (IFN-γ) and IL-12 were increased on day 1 after 
infection. IL-2 and TNF-α were detected in the plasma of CE0324F before 
infection (day 0). CE1242F showed low cytokine responses in IL-6, MCP- 
1, IL-10, IL-4, IL-13, MIP-1α, IFN-γ, and IL-12 compared with those in 
CE0324F. In CE0202M, levels of IL-8 and IL-12 on day 3 and levels of IL- 
13 from day 10 to day 17 were transiently increased, but no apparent 
changes in other cytokines were detected during the study. 
A neutralizing antibody against SARS-CoV-2 was detected in one 
macaque. A low titer of the neutralizing antibody against WK-521 was 
detected in CE0324F on day 10 after virus inoculation, but no neutral-
izing antibody was detected in the other two macaques until day 28 
(Table 2). An IgG response against SARS-CoV-2 S and N proteins was 
detected in the plasma of CE0324F and CE1242F after day 14 and day 
21, respectively, using an available antibody detection kit for human 
IgG/IgM, which seemed not to react to monkey IgM (Fig. S4). No anti-
body response against SARS-CoV-2 was detected in CE0202M, in which 
the number of BALTs was smaller than those in CE0324F and CE1242F 
(Fig. S3C), indicating a relationship between IgG responses and BALT 
formation. 
T lymphocyte responses specific for SARS-CoV-2 N protein and S 
protein were examined. In CE0324F, in which a neutralizing antibody 
was detected, increases in the numbers of IL-2 and IFN-γ-producing cells 
specific for SARS-CoV-2 N protein were seen on day 14 after virus 
inoculation (Fig. 7). In CE0202M, increases in the numbers of IFN- 
γ-producing cells and IL-2-producing cells were detected on day 14 and 
day 21, respectively. In CE1242F, increases in the numbers of IFN- 
γ-producing cells and IL-2-producing cells were detected on day 7 and 
day 14, respectively. In the two latter monkeys, the increase in the 
Fig. 4. Blood biochemistry in cynomolgus macaques infected with SARS-CoV- 
2. Biochemical analysis was performed using plasma collected on the indicated 
days after virus inoculation: (A) total bilirubin, (B) alanine aminotransferase, 
(C) alkaline phosphatase, (D) blood urea nitrogen, (E) creatinine, and 
(F) amylase. 
Fig. 5. Blood cell counts in cynomolgus macaques infected with SARS-CoV-2. 
Peripheral blood cells were collected on the indicated days after virus inocu-
lation. The concentrations of (A) total white blood cells, (B) granulocytes, (C) 
lymphocytes, (D) monocytes, and (E) platelets were determined. 
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number of IL-2-producing cells followed that of IFN-γ-producing cells 
and the stimulation indices of IFN-γ-producing cells were higher than 
those of IL-2-producing cells. Stimulation indices of IFN-γ-producing 
cells and IL-2-producing cells specific for SARS-CoV-2 S protein peptides 
were increased on day 28 compared with those before infection, but 
stimulation indices of IFN-γ-producing cells specific for SARS-CoV-2 S 
protein peptides were lower than those of IFN-γ-producing cells specific 
for SARS-CoV-2 N protein peptides (Fig. S5). 
3. Discussion 
We revealed the pathogenicity of SARS-CoV-2 in cynomolgus ma-
caques to establish an animal model for the development of vaccines and 
antiviral drugs. SARS-CoV-2 was detected predominantly in the nasal 
cavity and oral cavity of cynomolgus macaques for one week. Further-
more, infection with SARS-CoV-2 caused a body temperature rise in all 
of the cynomolgus macaques examined. However, radiographic viral 
pneumonia was observed in one macaque, in which a neutralizing 
antibody against SARS-CoV-2 was detected. Histologically, pneumonia 
in the repairing phase and/or bronchopneumonia were observed in all of 
the macaques and a thrombus in a pulmonary blood vessel was detected 
(Wichmann et al., 2020). Mild clinical signs of disease in the cynomolgus 
macaques in the present study are consistent with the results of previous 
studies using cynomolgus macaques and rhesus macaques (Rockx et al., 
2020; Munster et al., 2020) as well as the results of a clinical study 
showing that approximately 80% of human patients with COVID-19 did 
not show critical disease (Wiersinga et al., 2020). In addition, virus 
propagation in the respiratory tissue of cynomolgus macaques was 
confirmed, indicating that a cynomolgus macaque model is a suitable 
model for evaluation of the efficacy of vaccines and antiviral drugs. 
Plasma cytokine and chemokine responses were detected after 
infection with WK-521 in the cynomolgus macaques. The level of the 
representative inflammatory cytokine IL-6 in CE0324F, in which a 
neutralizing antibody was detected, was increased on day 1 after virus 
infection, but the increase in the level of this cytokine was transient at an 
early stage of infection and the inflammatory cytokine TNF-α was not 
increased at an early stage but was increased on day 17 in CE0324F. 
Therefore, no evidence of a cytokine storm or systemic inflammatory 
response syndrome was seen in the present study. On the other hand, a 
response of IL-4, a representative cytokine of a Th2 response, in plasma 
of CE0324F and a weak response of IL-13 in plasma of CE0202M and 
CE0324F were detected after day 10. Thus, the IL-4 response at a late 
Fig. 6. Levels of cytokines and chemokines in plasma of macaques infected with SARS-CoV-2. The concentrations of the indicated cytokines and chemokines in 
plasma collected on the indicated days from SARS-CoV-2-infected cynomolgus macaques are shown. 
Table 2 
Neutralizing antibody in macaques after infection with SARS-CoV-2.  
50% neutralization titer (log2) 
Days after virus inoculation CE0202M CE0324F CE1242F 
0 <a < <
7 < < <
10 < 3.00 <
14 < < <
17 < 3.00 <
21 < 4.00 <
24 < 4.23 <
28 < 5.00 <
a <: 50% neutralization titer was below 3 (23: detection limit). 
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phase of SARS-CoV-2 infection may be related to antibody production. 
An IL-17 response in plasma of CE0324F was detected at a late phase of 
SARS-CoV-2 infection, but the level was too low to discuss a role of IL-17 
in antibody production. 
No neutralizing antibody against SARS-CoV-2 was detected 28 days 
after virus inoculation in two macaques in which body temperature 
increased and the virus propagated. On the other hand, antibody re-
sponses specific for SARS-CoV-2 antigens were detected in most of the 
macaques on day 14 after infection in previous studies (Rockx et al., 
2020; Munster et al., 2020). The difference between our study and the 
other studies in the antibody response rate might be related to the age of 
macaques since some aged macaques (15–20 years of age) showed a 
weak antibody response against SARS-CoV-2 antigen in one of the pre-
vious studies (Rockx et al., 2020). Our results are consistent with the 
results of studies showing delayed IgG responses in human patients with 
COVID-19 (Zhao et al., 2020; Qu et al., 2020; Shen et al., 2020). The 
results of the present study indicate that delayed antibody responses 
would occur in patients without severe symptoms and complications. 
The results also suggested that the lack of an antibody against 
SARS-CoV-2 does not necessarily mean evidence of uninfected 
individuals. 
We also examined T-lymphocyte responses specific for SARS-CoV-2 
N and S protein peptides. In macaque CE0324F, in which a neutral-
izing antibody was detected, the number of cells producing IFN-γ and IL- 
2 specific for SARS-CoV-2 N protein was increased 2 weeks after virus 
inoculation. On the other hand, in CE0202M and CE1242F, in which no 
neutralizing antibody was detected, an increase in the number of cells 
producing IL-2 specific for SARS-CoV-2 N protein followed an increase 
in the number of cells producing IFN-γ. The results indicate that an IFN-γ 
response with a low IL-2 response is not sufficient for induction of a 
neutralizing antibody. In addition, the IFN-γ response (Th1 response) 
that helps so-called ‘cellular immunity’ might contribute to elimination 
of SARS-CoV-2 without a neutralizing antibody. Another possibility is 
that the early IFN-γ response in CE1242F was induced by memory Th1 
cells, suggesting previous exposure to other coronaviruses. The effects of 
immunity against the common cold coronavirus on SARS-CoV-2 infec-
tion will be analyzed using the macaque model in the future (Sette and 
Crotty 2020). 
The viral genes of SARS-CoV-2 were detected after day 10, although 
no infectious virus was detected in swab samples. Two possible reasons 
are thought to explain the discrepancy as seen in influenza B virus 
(Kitano et al., 2010). One is that the limit to detect infectious viruses 
using the cell culture was higher than that to detect the viral RNA using 
RT-PCR. The other is that viral genes and/or gene fragments were 
released from the infected cells without production of infectious viruses. 
Therefore, in macaques CE1242F and CE0202M that showed a low level 
and no detectable level of IgG responses against SARS-CoV-2 antigen 
without a detectable neutralizing antibody, very low levels of infectious 
virus and/or infected cells in the nasal cavity and the rectum might not 
be eliminated by the specific antibody until day 28. 
The level of amylase in the plasma of CE0324F was temporally 
increased. It has been reported that blood amylase was released from the 
injured pancreas in patients with COVID-19 pneumonia (Wang et al., 
2020b; Zhang et al., 2020). However, we did not detect inflammation or 
necrosis in the pancreas of macaques infected with SARS-CoV-2 at au-
topsy in the present study (data not shown). On the other hand, 
lymphoid infiltration in the submandibular gland of CE0324F might be 
related to the increase of plasma amylase (Liu et al., 2011), indicating 
that plasma amylase was derived from infected salivary glands and that 
the virus detection in oral swab samples was due to virus propagation in 
the salivary glands (J Xu et al., 2020), although a viral antigen was not 
detected in immunohistochemical staining of the salivary glands on day 
28, probably due to disappearance of the virus antigen before autopsy 
(data not shown). 
In comparison with other macaque studies, rhesus macaques showed 
visible clinical signs of disease after SARS-CoV-2 infection such as 
piloerection, hunched posture, and pale appearance (Munster et al., 
2020), which were not noticed in cynomolgus macaques in the present 
study and the previous study (Rockx et al., 2020). In the present study, 
significant body temperature rises in all of the cynomolgus macaques, 
especially at night, were recorded using a telemetry recording system, 
and such significant body temperature rises were not observed in the 
Fig. 7. Cytokine responses of T lymphocytes specific for SARS-CoV-2 N protein. 
Peripheral blood cells collected from macaques (A) CE0202M, (B) CE0324F, 
and (C) CE1242F on the indicated days were cultured for 24 h with peptides 
derived from SARS-CoV-2 N protein. The numbers of IFN-γ-positive and IL-2- 
positive cells were counted using an ELISPOT analyzer. Peptide-specific re-
sponses are indicated as a stimulation index = number of spots in the culture 
with peptides/number of spots in the culture without peptides. Left y-axis: 
stimulation index of IFN-γ, right y-axis: stimulation index of IL-2. Blue and red 
dotted lines indicate stimulation indexes of 2 in IFN-γ and IL-2, respectively. 
Stimulation indexes higher than 2 are considered to be responses specific for 
peptide antigens. 
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other studies including studies using rhesus macaques. Histological 
pneumonia was also detected in all of the infected cynomolgus ma-
caques in the present study. In addition, virus propagation in rhesus 
macaques, especially the duration of virus detection, was similar to that 
in cynomolgus macaques. Therefore, the cynomolgus macaque model is 
also thought to be a suitable animal model for evaluating the efficacy of 
vaccines and antiviral drug candidates for SARS-CoV-2 infection. 
In the present study, we revealed that SARS-CoV-2 propagated in the 
respiratory tissues of cynomolgus macaques and that SARS-CoV-2 
caused clinical signs of disease, indicating that the cynomolgus ma-
caque model is useful for the evaluation of vaccination and therapies. In 
addition, delayed and low antibody responses in the macaque model 
may explain the prolonged virus shedding and reinfection in human 
patients (Shi et al., 2020). 
4. Materials and methods 
4.1. Ethics statement 
This study was carried out in strict accordance with the Guidelines 
for the Husbandry and Management of Laboratory Animals of the 
Research Center for Animal Life Science at Shiga University of Medical 
Science and Standards Relating to the Care and Fundamental Guidelines 
for Proper Conduct of Animal Experiments and Related Activities in 
Academic Research Institutions under the jurisdiction of the Ministry of 
Education, Culture, Sports, Science and Technology, Japan. The pro-
tocols were approved by the Shiga University of Medical Science Animal 
Experiment Committee (permit number: 2020-4-2). Regular veterinary 
care and monitoring, balanced nutrition and environmental enrichment 
were provided by the Research Center for Animal Life Science at Shiga 
University of Medical Science. The macaques were euthanized at the 
endpoint (28 days after virus inoculation) using ketamine/xylazine 
followed by intravenous injection of pentobarbital (200 mg/kg). The 
animals were monitored every day during the study to be clinically 
scored as shown in Table S2 and to undergo veterinary examinations to 
help alleviate suffering. Animals would be euthanized if their clinical 
score reached 15 (a humane endpoint). 
4.2. Animals 
Fifteen-year-old and ten-year-old female cynomolgus macaques 
(CE0324F and CE1242F) and a fifteen-year-old male cynomolgus ma-
caque (CE0202M) were born at Shiga University of Medical Science 
from maternal parent macaques that originated from Indonesia and 
paternal parent macaques that originated from Vietnam. All procedures 
were performed under ketamine and xylazine anesthesia, and all efforts 
were made to minimize suffering. Food pellets of CMK-2 (CLEA Japan, 
Inc., Tokyo, Japan) were provided once a day after recovery from 
anesthesia and drinking water was available ad libitum. The animals 
were singly housed in cages equipped with bars to climb up for envi-
ronmental enrichment under controlled conditions of humidity (39%– 
61%), temperature (24–26 ◦C), and light (12-h light/12-h dark cycle, 
lights on at 8:00 a.m.). Two weeks before virus inoculation, a telemetry 
probe (M00, Data Sciences International, St. Paul, MN) was implanted in 
the peritoneal cavity or subcutaneous tissue of each macaque under 
ketamine/xylazine anesthesia followed by isoflurane inhalation to 
monitor body temperature. The macaques used in the present study 
were free from herpes B virus, hepatitis E virus, Mycobacterium tuber-
culosis, Shigella spp., Salmonella spp., and Entamoeba histolytica. 
Under ketamine/xylazine anesthesia, two cotton sticks (Eiken 
Chemical, Ltd., Tokyo, Japan) were used to collect fluid samples from 
the conjunctivas, nasal cavities, oral cavities and tracheas, and the sticks 
were subsequently immersed in 1 mL of minimal essential medium 
(MEM, Nacalai Tesque, Kyoto, Japan) containing 0.1% bovine serum 
albumin (BSA) and antibiotics. A bronchoscope (MEV-2560; Machida 
Endoscope Co. Ltd., Tokyo, Japan) and cytology brushes (BC-203D- 
2006; Olympus Co., Tokyo, Japan) were used to obtain bronchial sam-
ples. Samples were collected on indicated days. 
Chest X-ray radiographs were taken using the I-PACS system (Konica 
Minolta Inc., Tokyo, Japan) and PX-20BT mini (Kenko Tokina Corpo-
ration, Tokyo, Japan). SpO2 was measured with a pulse oximeter 
(Nellcor™, Medtronic plc, Dublin, Ireland). 
4.3. Virus and cells 
SARS-CoV-2 JP/TY/WK-521/2020 (WK-521) was used as a chal-
lenge strain (GenBank Sequence Accession: LC522975, kindly provided 
by Drs. Masayuki Saijo and Masaaki Sato, National Institute of Infectious 
Disease (NIID)) (Matsuyama et al., 2020). The nucleotide sequence of 
WK-521 has 99.9% similarity to that of the Wuhan-Hu-1 strain 
(NC_045512.2). WK-521 belongs to Group A and GISIAD clade S 
(Rambaut et al., 2020). The virus was propagated twice in NIID and once 
at the Shiga University of Medical Science using VeroE6 (American Type 
Culture Collection, Manassas, VA) in the presence of BIOMYC-3 (Bio-
logical Industries, Beit Haemek, Israel). 
The macaques were challenged with the WK-521 virus (2.2 × 106 
TCID50) inoculated into the conjunctiva (0.05 mL × 2), nostrils (0.5 mL 
× 2), oral cavity (0.9 mL), and trachea (5 mL) with pipettes and cath-
eters under ketamine/xylazine anesthesia. Experiments using the virus 
were performed in the biosafety level 3 facility of the Research Center 
for Animal Life Science, Shiga University of Medical Science. 
VeroE6 cells were grown in MEM supplemented with 10% inacti-
vated fetal bovine serum (Capricorn Scientific GmbH), penicillin (100 
units/mL), and streptomycin (100 μg/mL) (Nacalai Tesque). To assess 
virus replication, serial dilutions of swab samples and tissue homogenate 
samples (10% w/v) were inoculated onto confluent VeroE6 cells. The 
VeroE6 cells were cultured in MEM supplemented with 0.1% BSA, 
penicillin, streptomycin, gentamycin (50 μg/mL) (Fuji Film, Tokyo, 
Japan), and trypsin (5 μg/mL) (Nacalai Tesque). Cytopathic effects were 
examined under a microscope 6 days later. 
4.4. Quantitative PCR for the viral gene 
RNA was extracted from 140 μL of swab samples using the QiaAmp 
Viral RNA kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. Each sample was eluted with 60 μL of elution buffer, 
and 5 μL of extracted RNA was mixed with TaqMan Fast Virus 1-Step 
Master Mix (Thermo Fisher Scientific, Waltham, MA), primers and a 
probe in a reaction volume of 20 μL. Primers and probes developed by 
the Centers for Disease Control and Prevention (CDC) were used to 
detect the SARS-CoV-2 N protein gene (https://www.cdc.gov/coronavir 
us/2019-ncov/lab/rt-pcr-panel-primer-probes.html): forward primer 5′- 
GACCCCAAAATCAGCGAAAT-3‘(2019-nCoV_N1–F), reverse primer 5’ 
-TCTGGTTACTGCCAGTTGAATCTG-3‘(2019-nCoV_N1-R), and probe 5’- 
FAM-ACCCCGCATTACGTTTGG TGGACC-BHQ1-3‘ (2019-nCoV_N1–P). 
RT-PCR was performed on a CFX96 Touch Real-Time PCR Detection 
System (Bio-Rad Laboratories Inc., Hercules, CA) with the following 
cycle parameters: 5 min at 50 ◦C for reverse transcription, 20 s at 95 ◦C 
for initial denaturation followed by 45 cycles of 5 s at 95 ◦C and 30 s at 
60 ◦C. Standard RNA was a gift from Dr. Michinori Kohara, produced by 
cloning the N gene from hCoV-19/Japan/AI/I-004/2020 in a T7 plasmid 
expression system. In each run, dilutions of defined RNA standards were 
run in parallel to calculate copy numbers in the sample. 
4.5. Histopathological examination 
For histopathological examination, tissues obtained at autopsy were 
immersed in 10% neutral buffered formalin for fixation, embedded in 
paraffin, and cut into 3-μm-thick sections on glass slides. The sections 
were stained with hematoxylin and eosin (H & E) and observed under a 
light microscope. The number of BALT was counted in 8 H&E sections of 
6 lobes in each macaque by detection of follicle-like structures composed 
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of densely packed lymphocytes, of which the shortest diameter exceeded 
0.1 mm, and flanked by the bronchus or vessels. 
4.6. Blood cytokine and biochemical analyses 
Levels of cytokines/chemokines in macaque plasma were measured 
using the Milliplex MAP non-human primate cytokine panel and Lumi-
nex 200 (Millipore Corp., Billerica, MA) following the manufacturer’s 
instructions. Blood biochemical analysis and blood cell counts were 
performed using VetScan VS2 and HM2, respectively (Abaxis, Inc., 
Union City, CA). 
4.7. Virus neutralization assay 
Plasma samples were pretreated with a receptor-destroying enzyme 
(RDEII, Denka Seiken, Tokyo, Japan) at 37 ◦C overnight and then 
inactivated at 56 ◦C for 1 h. The diluted samples were mixed with 100 
TCID50/well of the WK-521 strain for 30 min. Then the mixture was 
added onto a VeroE6 monolayer in 96-well plates. After 1-h incubation, 
the cells were cultured in MEM containing 0.1% BSA and 5 μg/mL 
trypsin. After incubation at 37 ◦C for 6 days, the number of wells with 
cytopathic effects was counted in quadruplicate culture. Neutralization 
titers were expressed as the dilution in which cytopathic effects were 
observed in 50% of the wells. 
4.8. Detection of an antibody against SARS-CoV-2 
Plasma was collected on indicated days. A COVID-19 IgG/IgM 
immunodetection kit (Novus Biologicals USA, Centennial, CO) was used 
for detection of IgG and IgM specific for SARS-CoV-2 S and N proteins. 
Monkey IgM seemed not to react to the human IgM detection system. 
4.9. Detection of cytokine-producing cells in ELISPOT 
Peripheral blood mononuclear cells after separation from red blood 
cells were stored at − 80 ◦C until use. Thawed cells (5 × 105/well) were 
cultured with a peptide pool of SARS-CoV-2 N protein and S protein (0.6 
nmol/mL) (PepTivator, Miltenyi Biotech, Bergisch Gladbach, Germany) 
in the presence of anti-CD28 antibody (0.1 μg/mL) overnight in ELISPOT 
plates coated with anti–IFN-γ and IL-2 antibodies (Cellular Technology 
Limited, Shaker Heights, OH). The number of cytokine-producing cells 
was counted according to the manufacturer’s instructions. 
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